Первая фаза клинических испытаний противоопухолевой геномодифицированной вакцины. Оценка иммунного статуса

The study assessed response of immune system of patients with recurrent skin melanoma to vaccination by antitumor vaccine "Allogen" in phase I clinical trial. Vaccine 'Allogen" is prepared from irradiated melanoma cells Mel-Pol [1] that were transitorily transfected by gene Tag-7. Patients' blood lymphocyte subpopulation contents was determined by the panel of monoclonal antibodies against lymphocyte differentiation antigens before the initial vaccination and prior to every following vaccination. CD3, CD4, CD8, CD5, CD7, CD11b, CD16, CD25, CD38, CD71, CD95, CD56 antigen expression was analyzed. CD38/CD4, CD38/CD8, CD16b/CD16, CD11b/CD8, CD11b/CD56 antigen expression was assessed by double staining technique. The results showed that vaccination led to increased percentage of positive cells with activation antigens CD25, CD71, CD38, CD95.